Recent Data on the Treatment of Pulmonary Arterial Hypertension: An Expert Interview With Dr. Steven Nathan
The last decade has witnessed remarkable improvements in the understanding and treatment of pulmonary arterial hypertension (PAH). Data were presented at American College of Chest Physicians (ACCP) meeting on several studies focusing on new approaches to treating PAH.
Pittsburgh Researchers Find New Hope For Heart Patients - INTERESTING!
Thanks to a simple blood test, doctors no longer have to wait. Researchers at Allegheny General Hospital found that certain proteins and enzymes are elevated in patients with pulmonary hypertension -- the more severe the disease, the higher those levels. For the first time, a blood test can determine who does or doesn't have pulmonary hypertension, its severity and the disease's progression.
Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting
Soliris is the first product approved for the treatment of patients with PNH in the U.S. and Europe. PNH is a rare, debilitating and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. In patients with PNH, hemolysis can cause life-threatening thromboses, recurrent pain, kidney disease, disabling fatigue, impaired quality of life, severe anemia, pulmonary hypertension, shortness of breath and intermittent episodes of dark-colored urine (hemoglobinuria).
Anti-Blood-Clot Pill Could Cut Heart Problems - Study
Rivaroxaban is a new type of drug that targets an enzyme known as Factor Xa, which is involved in the blood-clotting process, while aspirin and Plavix, by
A Portable, Cheap Blood-Clotting Test
A new microsensor could help millions of patients who rely on blood-thinning drugs safely treat themselves.
Flu jabs halve threat of embolism in under-50s
Having a flu jab could almost halve the risk of developing venous thromboembolisms (VTE) among the under 50s, according to French research. The findings, presented at the annual AHA scientific sessions are the first to show that influenza vaccination can offer protection against VTEs, suc
Exercise can cut heart failure mortality risk - ALWAYS CHECK WITH YOUR OWN DOCTOR
Working out on a stationary bicycle or walking on a treadmill just 25 to 30 minutes daily can modestly reduce hospitalisation or death risk in
The HF-ACTION trial (A Controlled Trial Investigating Outcomes Exercise Training) led by Dr Christopher O'Connor, director of the Duke Heart Centre showed that exercising improved outcomes for patients who have suffered heart failure.
Researchers look at sildenafil use in cirrhosis patients
Sildenafil is valuable in the treatment of erectile dysfunction and pulmonary hypertension in patients with end-stage liver disease through inhibition of the type-5 phosphodiesterase. The type-5 phosphodiesterase is also present in human mesenteric arteries.
Plavix plus Heartburn Drugs Boost Patients’ Risk for Cardiac Events
A Medco Health Solutions study presented Tuesday at the American Heart Association meeting in New Orleans reveals that stent patient taking Sanofi-Aventis/Bristol-Myers Squibb’s blood thinner block buster Plavix or clopidogrel along with certain heartburn drugs such as AstraZeneca PLC's Nexium may face a greater risk of heart attack, stroke and other dangerous events than those who took Plavix alone.